Last quarter (Q4 2022), Clinuvel Pharmaceuticals Limited's total revenue was $41.40M, a decrease of ― from the same quarter last year. In Q4, Clinuvel Pharmaceuticals Limited's net income was $―. See Clinuvel Pharmaceuticals Limited’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	$ 121.94M	$ 78.32M	$ 65.72M	$ 47.98M	$ 32.57M	$ 31.05M
Cost of Revenue	$ ―	$ ―	$ 10.48M	$ 4.72M	$ 9.63M	$ 6.87M
Gross Profit	$ ―	$ ―	$ 55.24M	$ 43.26M	$ 22.94M	$ 24.18M
Operating Expense	$ ―	$ ―	$ 19.91M	$ 15.03M	$ 11.55M	$ 7.49M
Operating Income	$ ―	$ ―	$ 35.33M	$ 28.22M	$ 11.39M	$ 16.69M
Net Non Operating Interest Income Expense	$ ―	$ ―	$ -1.83M	$ -1.28M	$ 537.04K	$ 543.54K
Other Income Expense	$ ―	$ ―	$ 821.15K	$ -1.24M	$ 781.32K	$ 880.48K
Pretax Income	$ ―	$ ―	$ 34.32M	$ 25.71M	$ 13.14M	$ 18.11M
Tax Provision	$ ―	$ ―	$ 13.44M	$ 984.40K	$ -3.51M	$ -19.33K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ ―	$ 20.88M	$ 24.73M	$ 16.65M	$ 18.13M
Basic EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Basic Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ ―	$ 20.88M	$ 24.73M	$ 16.65M	$ 18.13M
Normalized Income	$ ―	$ ―	$ 20.88M	$ 24.73M	$ 16.65M	$ 18.13M
Interest Expense	$ ―	$ ―	$ 2.27M	$ 1.62M	$ 25.89K	$ 21.11K
EBIT	$ ―	$ ―	$ 36.60M	$ 27.33M	$ 13.16M	$ 18.14M
EBITDA	$ ―	$ 49.56M	$ 37.35M	$ 28.19M	$ 13.59M	$ 18.14M

Currency in USD

Clinuvel Pharmaceuticals Limited Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing